What hurdles in delivering new modalities, like biologics, are you seeing? Delivery is really the key. We know, if we conduct experiments in the laboratory on cells, we can get incredible results. We ...

As genomic medicine advances beyond early proof-of-concept therapies, the field is facing an increasingly urgent challenge: delivery, not payload design, is now the primary bottleneck. While genetic ...

Extracellular vesicles (EVs) are gaining ground as next-generation drug delivery modalities. Genetic fusion of the protein of interest to a scaffold protein with high EV-sorting ability represents a ...

For decades, drug developers have been confronted by the stubborn reality that most of the targets inside cells remain undruggable. Estimates suggest that as many as 85% of intracellular proteins ...